Literature DB >> 6432714

Reduction of the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition.

G Covi, P Minuz, G Capuzzo, C Lechi, P Delva, A Lechi.   

Abstract

The effects of prostaglandin synthetase inhibition by indomethacin on blood pressure and hormonal variations induced by captopril were studied in eight patients with essential hypertension and in six nonhypertensive subjects. Captopril antihypertensive effect and captopril-induced plasma renin increase were almost totally abolished by a short-term administration of indomethacin (50 mg t.i.d.). These results support the hypothesis that prostaglandins contribute to the antihypertensive effects of ACE inhibitors. It may be of clinical importance that anti-inflammatory drugs that inhibit PG-synthetase can also blunt the antihypertensive action of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432714

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  4 in total

Review 1.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 2.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 3.  Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.

Authors:  H Shanthanna; N H Strand; D A Provenzano; C A Lobo; S Eldabe; A Bhatia; J Wegener; K Curtis; S P Cohen; S Narouze
Journal:  Anaesthesia       Date:  2020-04-26       Impact factor: 6.955

Review 4.  A Review: The Manifestations, Mechanisms, and Treatments of Musculoskeletal Pain in Patients With COVID-19.

Authors:  Lijuan Wang; Na Yang; Jinfeng Yang; Shuwu Zhao; Chen Su
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.